Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

iwMyeloma 2017 | The future of immunotherapy in multiple myeloma

Hearn Jay Cho, Ivan Borrello and Tuna Mutis • 18 Oct 2017
iwMyeloma 2017
Multiple Myeloma Antibodies Checkpoint inhibitors Vaccines

There is a plethora of therapies available for multiple myeloma (MM). In this insightful panel discussion at the Myeloma 2017 meeting in Edinburgh, UK, Ivan Marques Borrello, MD from John Hopkins School of Medicine, Baltimore, MD, Hearn Cho, MD, PhD from Mount Sinai School of Medicine, New York, NY and Tuna Mutis, MD, PhD from the VU University Medical Center, Amsterdam, Netherlands, discuss the current state of immunotherapy for MM and what the future holds. They share their thoughts on combination therapies, creating more broadly applicable therapies, checkpoint inhibitor trials and bispecific antibodies.

More from Hearn Jay Cho

Ongoing research at the MMRF: Horizon Clinical Trials Program
12:24
Ongoing research at the MMRF: Horizon Clinical Trials Program
Hearn Jay Cho et al. • 11 Apr 2025
History and upcoming projects of the MMRF
History and upcoming projects of the MMRF
Hearn Jay Cho et al. • 3 May 2024
Novel targets in 2022
10:01
Novel targets in 2022
Hearn Jay Cho et al. • 26 Mar 2022

More from Ivan Borrello

The role of the microenvironment in multiple myeloma
15:05
The role of the microenvironment in multiple myeloma
Hearn Jay Cho et al. • 9 Sep 2018
Adoptive T-cell therapy for the treatment of MM
2:18
Adoptive T-cell therapy for the treatment of MM
Hearn Jay Cho et al. • 22 Jun 2017
Using vaccines to impart a long-term response in lenalidomide-treated MM
1:07
Using vaccines to impart a long-term response in lenalidomide-treated MM
Hearn Jay Cho et al. • 22 Jun 2017
Myeloma 2016: Panel discussion on gene modified T-cells
9:13
Myeloma 2016: Panel discussion on gene modified T-cells
Hearn Jay Cho et al. • 22 Apr 2016

More from Tuna Mutis

Focusing on allogeneic CAR T-cell therapies for myeloma
0:57
Focusing on allogeneic CAR T-cell therapies for myeloma
Hearn Jay Cho et al. • 1 Apr 2022
Highlights from ICLE 2022
0:52
Highlights from ICLE 2022
Hearn Jay Cho et al. • 1 Apr 2022
Current research on anti-CD38 CAR T-cell therapies
1:09
Current research on anti-CD38 CAR T-cell therapies
Hearn Jay Cho et al. • 1 Apr 2022
Relapsing from CAR T-cells in multiple myeloma
2:15
Relapsing from CAR T-cells in multiple myeloma
Hearn Jay Cho et al. • 1 Apr 2022

Related Videos

Impact of Duffy status on PFS in newly diagnosed multiple myeloma treated with RVd ± autoSCT
4:13
Impact of Duffy status on PFS in newly diagnosed multiple myeloma treated with RVd ± autoSCT
Hearn Jay Cho et al. • 7 Dec 2025
Key multiple myeloma breakthroughs at ASH 2025
6:04
Key multiple myeloma breakthroughs at ASH 2025
Hearn Jay Cho et al. • 7 Dec 2025
A dual-targeting BCMA and CD19 FasTCAR-T (GC012F/AZD0120) as 1L therapy for newly diagnosed myeloma
4:18
A dual-targeting BCMA and CD19 FasTCAR-T (GC012F/AZD0120) as 1L therapy for newly diagnosed myeloma
Hearn Jay Cho et al. • 7 Dec 2025
Ultra-deep WGS of cell-free DNA to detect bone marrow-derived mutations in multiple myeloma
2:29
Ultra-deep WGS of cell-free DNA to detect bone marrow-derived mutations in multiple myeloma
Hearn Jay Cho et al. • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals